Tesamorelin and Frailty in Older Adults With HIV: What the TRIUMPH Trial Is Testing

The newly published TRIUMPH paper is a trial protocol, not a results paper and not the launch of a new trial. PMID 42419889 describes how an already-running, recruiting Phase 2 study will test whether tesamorelin adds physical-function benefits to exercise in a specific group of older adults with HIV. Every participant exercises. No efficacy result has been reported.

My read is that TRIUMPH asks the right question. A change in abdominal fat or muscle area can be biologically interesting, but it does not by itself show that a person stands, walks, or functions better. This protocol puts repeated chair stands at the center and surrounds that endpoint with walking, strength, frailty, muscle-quality, and quality-of-life measures.

The New TRIUMPH Publication Is a Protocol for an Existing Trial

Erlandson and colleagues published the TRIUMPH protocol in BMJ Open on July 8, 2026 (DOI: 10.1136/bmjopen-2026-120740). The paper is formally classified as a clinical trial protocol.

The underlying study is not new. ClinicalTrials.gov record NCT06554717 was first posted on August 15, 2024, lists an actual start date of July 10, 2025, and was recruiting when the registry was last verified in May 2026. The estimated primary completion is June 2028, followed by estimated study completion in December 2028.

That timeline prevents three common misreadings:

1. The protocol publication is not a trial result. It states planned methods and outcomes.
2. The publication is not a new trial launch. Enrollment activity began before the paper appeared.
3. Recruiting status is not evidence of benefit. It only describes the operational state of the study.

What the TRIUMPH Phase 2 Trial Is Testing

TRIUMPH is a two-site, randomized, masked, placebo-controlled Phase 2 trial with an estimated enrollment of 100 participants. The sites are Massachusetts General Hospital in Boston and the University of Colorado Anschutz Medical Campus in Aurora.

The controlled comparison is straightforward:

• one group receives tesamorelin plus a home-based, semi-supervised exercise program;
• the other receives placebo plus the same exercise program.

All participants exercise during the 24-week intervention. TRIUMPH therefore does not test tesamorelin against doing nothing, and it does not isolate the effect of exercise itself. It asks whether tesamorelin provides an incremental effect when added to a shared exercise program.

The study path is:

1. Eligible participants complete baseline assessments.
2. Participants are randomized to tesamorelin or placebo, with exercise in both groups.
3. The intervention continues for 24 weeks.
4. Participants enter a further 24-week extension off study drug and supervised exercise, with encouragement to exercise independently.
5. Investigators assess short-term outcomes at Week 24 and whether any changes persist at Week 48.

That extension is a strength. A Week 24 difference could disappear when the study intervention stops. Persistence at Week 48 would make the finding more informative, although the off-treatment phase will also make adherence and behavior harder to control.

TRIUMPH Makes Physical Function the Primary Test

The primary outcome is the change from baseline to Week 24 in the time required to complete 10 repeated chair stands. That is a performance endpoint, not a scan-derived estimate of body composition.

The wider endpoint set lets investigators ask whether any chair-stand difference is supported by related changes:

Domain	Listed measure	What it can clarify
Primary physical function	Time for 10 repeated chair stands	Whether lower-body performance changes by Week 24
Global lower-body function	Standard and modified Short Physical Performance Battery	Balance, gait, and strength performance
Strength	One-repetition maximum leg press	Whether maximal lower-extremity strength changes
Walking capacity	400-meter walk time	Whether performance extends beyond a brief chair task
Frailty	Fried frailty phenotype	Whether weakness, slowness, exhaustion, activity, and weight-loss criteria shift together
Muscle amount	Appendicular lean tissue by DXA; trunk and thigh muscle area by CT	Whether tissue quantity changes alongside function
Muscle quality	CT muscle density; protocol-specified muscle fat and mitochondrial measures	Whether tissue characteristics change, not just size
Lived and behavioral outcomes	SF-36 quality of life, exercise self-efficacy, and adherence	Whether measured performance aligns with how participants feel and engage

No single secondary endpoint can rescue a negative primary outcome. The value of the set is convergence. Faster chair stands supported by better walking, strength, and frailty measures would be more persuasive than a scan showing additional lean tissue without functional improvement.

Why Function Matters Beyond Body Composition

Body composition describes tissue compartments. Physical function describes what a person can do. The two can move together, but they are not interchangeable.

This distinction is especially relevant in older adults with HIV. In the PREPARE ancillary study of the REPRIEVE trial, physical-function impairment and frailty were present among middle-aged people with HIV despite modern care (PMID: 32645163). Earlier cohort evidence associated frailty with recurrent falls in older adults with HIV (PMID: 28991026) and linked a frailty-related phenotype before antiretroviral therapy with later AIDS or death (PMID: 21719610). Those observational findings do not prove that changing a chair-stand time will prevent those outcomes, but they explain why function is not a cosmetic endpoint.

Prior tesamorelin evidence also makes the separation necessary. A 2019 analysis reported decreased muscle fat and increased muscle area in adults with HIV (PMID: 31237318). That is a rationale for TRIUMPH, not proof of improved performance. Muscle area on imaging cannot tell us whether someone can rise from a chair more quickly, walk 400 meters faster, or experience less frailty.

Exercise evidence creates a second reason to focus on function. A randomized study in older adults with and without HIV found physical-function improvements with exercise (PMID: 30134299). Because exercise is active in both TRIUMPH groups, the eventual between-group difference must exceed the improvement that the shared program produces. That is a more demanding and more clinically useful comparison than attributing every change in the intervention group to tesamorelin.

This endpoint discipline is similar to the issue I discussed in the GRAMS trial commentary on tirzepatide and muscle loss: tissue quantity is not a complete substitute for tissue quality or performance. My research methodology also explains why I separate planned outcomes from observed findings and primary endpoints from exploratory signals.

The TRIUMPH Population Sets Narrow Limits

The trial does not enroll a general population of older adults. The registry specifies adults ages 50 to 80 who:

• have documented HIV with suppressive antiretroviral therapy and protocol-defined virologic and immune criteria;
• report a sedentary lifestyle;
• meet at least one Fried frailty criterion;
• have excess abdominal adiposity under protocol-defined anthropometric thresholds; and
• receive provider approval to participate.

The exclusion criteria further narrow interpretation by screening out several health conditions, recent therapies, unstable cardiovascular disease, active or recent malignancy in most circumstances, and factors that could affect the growth hormone and IGF-1 axis.

If TRIUMPH is positive, it will apply most directly to people resembling those participants. It will not establish tesamorelin as a general treatment for aging, frailty without HIV, athletic performance, or healthy longevity. It will also offer limited direct evidence for people with uncontrolled HIV, regular resistance-training experience, or clinical profiles excluded from enrollment.

A sample of 100 across two US centers is suitable for a focused Phase 2 signal, but it will not settle rare safety questions or prove effects on falls, disability, hospitalization, or survival. Those are not the registered primary outcome.

What Eventual TRIUMPH Results Would Need to Show

A convincing positive result would need more than a favorable body-composition scan.

First, the prespecified primary analysis should show a credible between-group improvement in repeated chair-stand time at Week 24. The comparison must remain tesamorelin plus exercise versus placebo plus exercise, not before-and-after change in only one group.

Second, the magnitude should be functionally meaningful, not merely statistically detectable. The protocol’s eventual report should present absolute changes, uncertainty intervals, missing-data handling, and enough context to judge whether the difference is noticeable in daily function.

Third, related endpoints should point in a coherent direction. Better chair stands accompanied by stronger leg press performance, faster walking, or improved SPPB and frailty measures would strengthen the claim. A larger muscle area with no performance gain would support a body-composition effect, not a functional one.

Fourth, Week 48 data should show whether any benefit persists after study drug and supervised exercise end. Durability will be difficult to interpret unless the report clearly describes independent exercise adherence in both groups.

Fifth, safety, withdrawals, adherence, and blinding need equal visibility. A functional signal cannot be interpreted responsibly without knowing who completed the trial, whether exercise exposure differed between groups, and what adverse events occurred.

Finally, the language must stay inside the enrolled population and measured outcomes. Even a clean Phase 2 result would justify a larger confirmatory study, not extrapolation to general anti-aging or performance use.

My Read Before TRIUMPH Reports Results

TRIUMPH is worth watching because it refuses to treat body composition as the final outcome. Its strongest design choice is also the easiest one to miss: every participant exercises, and the primary endpoint asks what added effect appears in physical performance.

The protocol cannot tell us whether tesamorelin improves frailty or function. It tells us how investigators plan to find out. Until participant data are reported, any efficacy claim outruns the evidence.

Medical disclaimer: This commentary is for research education only. It does not provide diagnosis, treatment, medication, exercise, or participation advice. Questions about HIV care, frailty, clinical-trial eligibility, or prescribed therapy belong with a qualified healthcare professional and the official study team.

Primary Sources and References

• Erlandson KM et al. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026;16:e120740. PMID: 42419889. DOI: 10.1136/bmjopen-2026-120740.
• ClinicalTrials.gov. NCT06554717: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV. Recruiting status and study record verified May 2026.
• Umbleja T et al. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. Journal of Infectious Diseases. 2020. PMID: 32645163. DOI: 10.1093/infdis/jiaa249.
• Tassiopoulos K et al. Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults. AIDS. 2017. PMID: 28991026. DOI: 10.1097/QAD.0000000000001613.
• Desquilbet L et al. A Frailty-Related Phenotype Before HAART Initiation as an Independent Risk Factor for AIDS or Death After HAART Among HIV-Infected Men. Journal of Gerontology: Series A. 2011. PMID: 21719610. DOI: 10.1093/gerona/glr097.
• Adrian S et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. Journal of Frailty & Aging. 2019. PMID: 31237318. DOI: 10.14283/jfa.2018.45.
• Erlandson KM et al. Physical function improvements with moderate or high-intensity exercise among older adults with or without HIV infection. AIDS. 2018. PMID: 30134299. DOI: 10.1097/QAD.0000000000001984.